Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05112991

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Conditions Advanced Endometrial Cancer

Interventions Envafolimab Envafolimab+Lenvatinib

Updated 11 times since 2021 Last updated: May 27, 2025 Started: Mar 4, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Endometrial Cancer, this trial is actively recruiting participants. The trial is conducted by 3D Medicines (Sichuan) Co., Ltd. and has accumulated 11 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jun 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2

▶ Show 6 earlier versions

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Feb 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Jul 2022 — Feb 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE2
Dec 2021 — Apr 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

3D Medicines (Sichuan) Co., Ltd.

Data source: 3D Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chongqing, China , Fuzhou, China , Ganzhou, China , Guangzhou, China , Hangzhou, China , Jinan, China , Linyi, China , Nanjing, China and 7 more locations